Synthesis Innovation

PEPTIDE SYNTHESIS: THE DRIVING FORCE OF THE PEPTIDE GOLDEN ERA

Fernando Albericio[1,2]



[1]Peptide Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa
[2]Department of Inorganic and Organic Chemistry, University of Barcelona, Barcelona, Spain

Abstract

Peptides have evolved from biochemical tools into a major class of therapeutic agents, propelled by the success of drugs such as semaglutide and tirzepatide. Their large-scale production has transformed peptide chemistry into an industrial discipline requiring multi-ton synthesis capacity and sustainable manufacturing solutions. Advances in solid-phase (SPPS), liquid-phase (LPPS), and hybrid synthesis, together with native chemical ligation (NCL), have enabled the efficient preparation of long and branched peptides. However, this rapid growth has revealed key challenges, including, the environmental impact of solvents and reagents, the need for greener synthetic strategies, sustainable methods for the large scale amounts demanded by the market, and limited availability of trained peptide chemists. Current efforts focus on developing low-swelling resins, alternative protecting groups to Fmoc, and solvent reduction strategies in line with Green Chemistry principles. Collaboration between academia, contract manufacturers, and pharmaceutical companies will be crucial to achieving sustainable, scalable peptide synthesis for future therapeutic demands.

Introduction

This synthesis-driven revolution now defines what many call the Peptide Golden Era—a convergence of science, industry, and sustainability that requires global collaboration. For many years, the use of the word “peptide” was confined to a strictly scientific context. However, a few years ago, with the discovery of semaglutide and later tirzepatide, peptides have become the new “rock stars”, frequently featured in mass media, television, newspapers, and social networks. The Peptide Drug Hunting Consortium (PDHC) has emphasized that sustainable peptide synthesis is not just a technical challenge but a community responsibility. By connecting academic innovators, CDMOs, and therapeutic developers, PDHC initiatives aim to accelerate scalable, green peptide manufacturing practices and to disseminate shared best practices across the ecosystem. Today, the pharmaceutical industry requires tons of these peptides each year. In the case of tirzepatide, production relies entirely on chemical synthesis, whereas semaglutide is obtained either through semi-synthesis—a combination of biotechnological and chemical methods—or through purely chemical synthesis.

In the middle of the last century, such a scenario would have been unimaginable. Peptides were regarded merely as biochemical tools that could be synthesized, but not on a scale suitable for mass consumption. Figure 1 shows the milestones Driving the Peptide Golden Era.

In 1954, Vincent du Vigneaud achieved the first chemical synthesis of an active peptide, oxytocin, a milestone that earned him the Nobel Prize in Chemistry in 1955.[1] Although this synthesis was a true breakthrough, it did not yet allow scientists to foresee the crucial role peptides would later play in the pharmaceutical field.



Figure 1. Milestones Driving the Peptide Golden Era: Key advances in chemical peptide synthesis.

In 1963, Bruce Merrifield introduced a revolutionary approach to peptide synthesis — the Solid Phase Peptide Synthesis (SPPS) method.[2] In this technique, the C-terminal of the growing peptide is anchored to an insoluble polymeric support, which allows the use of excess reagents to ensure good yields in each reaction step. The unreacted reagents and soluble by-products can then be removed simply by filtration and washing. Although SPPS initially faced significant criticism, particularly from European researchers,[3] it gradually became the method of choice for peptide synthesis. Merrifield's contribution was later recognized with the Nobel Prize in Chemistry in 1984.

In the 1970s, Lou Carpino introduced the fluorenyloxycarbonyl (Fmoc) group for α-amino protection,[4] likely without realizing how profoundly this innovation would influence the future of pharmaceutical peptides. The Fmoc group, which is removed by a β-elimination reaction in the presence of secondary amines, can be used in combination with tert-butyl (tBu) protecting groups for side chains, which are removable under mild acidic conditions such as trifluoroacetic acid (TFA). This Fmoc/tBu protection strategy replaced the earlier tert-butoxycarbonyl (Boc)/benzyl (Bzl) approach developed in Merrifield's laboratory, which required harsh reagents like hydrogen fluoride (HF) or trifluoromethanesulfonic acid (TFMSA) for deprotection. The adoption of the Fmoc/tBu system was strongly promoted by two research groups: one in Europe, led by Bob Sheppard and Eric Atherton,[5] and another in the United States at Hoffmann-La Roche, led by Johannes Meienhofer and Art Felix.[6] Hoffmann-La Roche was among the first pharmaceutical companies to recognize the therapeutic potential of peptides. Although the chemical synthesis of peptides was already established, a key factor in its consolidation occurred in the 1960s, when Jim Waters founded Waters Corporation, marking the beginning of modern chromatography. Later, Jean Rivier introduced reverse-phase chromatography for the industrial-scale purification of peptides, a major step toward large-scale peptide production.[7]

In 1994, Phil Dawson and Steve Kent developed the Native Chemical Ligation (NCL) method for the synthesis of large peptides and proteins.[8] Briefly, this strategy involves coupling unprotected peptide segments in aqueous media through a thioester-mediated reaction between an N-terminal cysteine-containing peptide and another C-terminal peptide thioester, followed by a rearrangement to form a native peptide (amide) bond. These unprotected peptide fragments are synthesized via SPPS, and because they lack protecting groups, they generally do not exhibit solubility issues in aqueous conditions.

Trimeris/Roche were the first to produce a large therapeutic peptide—the 36-amino-acid T20 (enfuvirtide)—on a multi-kilogram

scale for HIV treatment.[9] They employed a hybrid solid-phase/solution strategy, in which protected peptides synthesized on solid support were subsequently assembled in solution. The production of T20/enfuvirtide marked a kind of "democratization" of peptide manufacturing. For instance, CBL Patras, a small biotech company founded by the academic peptide chemist Kleominas Barlos in Patras, Greece, established within a year a facility capable of producing 2-chlorotrityl chloride (CTC) resin—essential for solid-phase peptide synthesis—on a multi-kilogram scale.[10] This development significantly lowered the prices of CTC resin and most Fmoc-protected amino acids, except Fmoc-Arg(Pbf)-OH, which remains challenging to synthesize and is absent from the T20/enfuvirtide sequence. The resulting cost reduction benefited both academic and industrial peptide research.

The same hybrid synthesis approach is now used for the production of tirzepatide, a 39-amino-acid peptide with a branched structure containing four moieties, developed by Eli Lilly.[11] Initially designed for the treatment of type 2 diabetes, tirzepatide is now also approved for obesity, requiring production volumes measured in tons. It acts as a dual agonist of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors.

For the same therapeutic indications, semaglutide—a 31-amino-acid peptide with a branch containing two moieties—is produced by Novo Nordisk using a semi-synthetic strategy. In this approach, an unprotected linear peptide obtained biotechnologically is chemically modified by attaching the side-chain branch, followed by coupling of the C-terminal segment, which contains the non-proteinogenic amino acid Aib (α-aminoisobutyric acid). This strategy cannot be applied to tirzepatide because it contains an additional Aib residue within its linear sequence.

As the semaglutide patent nears expiration, numerous CDMOs (Contract Development and Manufacturing Organizations) and pharmaceutical companies are developing fully synthetic or hybrid manufacturing routes. The GLP-1 agonist field continues to expand rapidly, with several large peptides currently in advanced clinical trials, including retatrutide and mazdutide (Eli Lilly), cagrilintide (Novo Nordisk), survodutide (Boehringer Ingelheim), and pemvidutide (Altimmune), among others.

This situation represents a true earthquake in the peptide chemistry ecosystem, whose long-term repercussions are still difficult to predict. To meet the growing demand, Western CDMOs are doubling their production capacities; in China, CDMOs that traditionally focused on small molecules are launching peptide programs with reactors of several thousand liters; and in India, the Indian Peptide Society estimates that hundreds of CDMOs have already been established across the country.

However, one of the most critical challenges remains the shortage of well-trained peptide chemists to support this rapidly expanding field. The PDHC aspires to develop mentorship and training opportunities and to connect CRO technologies through our EBN in process peptide chemistry to help close the gap.

The current momentum in peptide-based drugs for diabetes and obesity has coincided with another major global trend — sustainability — which has fuelled numerous initiatives inspired by Green Chemistry. As defined by Paul Anastas, Green Chemistry is "the design of chemical products and processes to reduce or eliminate the use and generation of hazardous substances."[12]

In parallel, PDHC is convening roundtables on green process metrics (PMI/E-factor), DMF alternatives, low-swelling resins, and one-pot SPPS cycles to accelerate adoption of pragmatic, scalable practices.

In addition to efforts aimed at identifying greener solvents for synthesis, non-solvents for work-up, bases for the removal of temporary protecting groups, and acids for final global deprotection and cleavage (topics that will be discussed later), recent years have also witnessed a revival of an older strategy originally proposed by Manfred Mutter and Ernst Bayer in the 1970s: the Liquid-Phase Peptide Synthesis (LPPS) method.[13]

LPPS, like SPPS, is a continuous process, but instead of anchoring the growing peptide to an insoluble solid support, it is attached to a soluble polymer. After each synthetic step, the peptide–polymer conjugate is separated from excess reagents and soluble by-products through precipitation and filtration or ultrafiltration. LPPS thus combines the advantages of both classical solution-phase synthesis and SPPS: the reactions occur in homogeneous solution, allowing the use of smaller reagent excesses, while maintaining simple and efficient purification

steps.
Over the years, the original concept of LPPS developed by Mutter and Bayer has evolved considerably, now involving hydrophobic soluble polymers or even small discrete hydrophobic molecules known as tags. In these modern variants, the growing peptide can be isolated either by precipitation or by liquid–liquid extraction in aqueous media.[14]
It is important to distinguish LPPS from classical solution-phase peptide synthesis, as employed by du Vigneaud for the synthesis of oxytocin. The term LPPS should be reserved for continuous processes where peptide elongation occurs on a soluble polymer or tag, following the same conceptual framework as SPPS.[15]
Beyond the large branched peptides such as semaglutide and tirzepatide, which incorporate fatty acid chains to substantially extend their half-lives in the human body, another emerging and highly significant class comprises mono-, bi- and tri-cyclic peptides of approximately 15 amino acids. Most of these molecules have been identified by PeptiDream, the Japanese company founded by Hiroaki Suga,[16] or through phage display technologies developed by Sir Gregory Winter,[17] who won the Nobel Prize in Chemistry in 2018 and whose work underpins the company Bicycle Therapeutics.
These condensed polycyclic peptides typically contain non-proteinogenic amino acids and synthetic chemical moieties such as thioethers, products of click chemistry (as developed, among others, by the 2022 Nobel Laureate in Chemistry, Morten Meldal,[18] himself an accomplished peptide chemist), as well as metathesis or cross-coupling reactions. The result is a rigid and highly stable scaffold, functionally and structurally approaching that of small molecules.
With this panorama — and a forecast predicting a GLP-1 market of USD 100–150 billion by 2030 and approximately 9% of the U.S. population using GLP-1 analogues by that year — the outlook for peptide therapeutics is extraordinary. While business leaders see billions of dollars in revenue, peptide chemists foresee multi-tons of resins/tags, Fmoc-amino acids, solvents, reagents, and inevitably, waste. The key question, therefore, is: what is the future of peptide synthesis?
At the research scale, SPPS remains the method of choice. A wide variety of high-performance resins are available, and together with an extensive range of peptide synthesizers—in which heating systems (conventional, microwave, or infrared) have been implemented for all synthetic steps—allow the preparation of peptides in milligram-to-gram scales with sufficient purity for early-stage drug discovery.
For larger peptides and small to medium-size proteins, Native Chemical Ligation (NCL) is the preferred technique. To extend the applicability of NCL, cysteine residues can be strategically placed at alanine positions in the target sequence, followed by desulfurization, thereby regenerating the native Ala residue.19 This desulfurization strategy has been extended to other β-thiol amino acids, which can serve as chemical precursors of proteinogenic residues, thereby expanding the ligation sites available for fragment coupling. Thus, in research environments and early drug discovery, peptide availability is no longer a bottleneck. However, the major challenge lies in industrial manufacturing.

α-Amino Protection

Since the introduction of the Fmoc protecting group by Lou Carpino[4] and its adoption in SPPS, the Fmoc/tBu strategy has been the standard due to its avoidance of strong acids. Nevertheless, Fmoc is far from ideal. It is not environmentally friendly, as it is derived from coal-based chemistry, and its bulky aromatic structure results in poor atom economy—only a small fraction of its atoms end up in the final peptide. For instance, the atom economy is 0.40 for Fmoc-Phe-OH and 0.19 for Fmoc-Gly-OH, the highest and lowest values, respectively, among all proteinogenic amino acids. Moreover, the aromatic, hydrophobic nature of Fmoc promotes π–π interactions—either between Fmoc groups on different peptide chains or between Fmoc and aromatic moieties within the peptide–resin complex. These interactions can lead to peptide aggregation, hindering both coupling efficiency and Fmoc removal, often resulting in deletion peptides.
To our knowledge, at least four academic–industrial collaborations have attempted to introduce alternative Nα-protecting groups: (i) Barany (in collaboration with Bioresearch, San Francisco) proposed Nα-dithiasuccinoyl (Dts), removable

in the presence of thiols;[20] (ii) Carpino, first with Waters-Millipore and later with CEM, developed 1,1-dioxobenzo[b] thiophene-2-ylmethyloxycarbonyl (Bsmoc), removable via Michael addition with secondary amines;[21] (iii) Hack-Joo Kim and Vladimir Sabirov in collaboration with Hyundai Pharm introduced 2-(4-nitrophenylsulfonyl)ethoxycarbonyl (Nsc), removable similarly to Fmoc through β-elimination in the presence of secondary amines;[22] (iv) Most recently, Harald Kolmar and Sulfotools proposed Smoc-amino acids (2,7-disulfo-9-fluorenylmethoxycarbonyl), which are bis-sulfonated Fmoc analogues.[23] The sulfonate groups impart water solubility to the Smoc-amino acids. The first three strategies, however, did not progress beyond early studies, and the Smoc approach still requires demonstration of its feasibility for large-scale peptide synthesis.

Although Fmoc is imperfect, its replacement poses formidable challenges. A new protecting group cannot be acid-labile, since acid treatment is reserved for side-chain deprotection and peptide cleavage from the resin in SPPS. Designing a group removable by basic conditions is also problematic, as it must coexist with the nucleophilic amino group, which itself could remove the protecting group from incoming monomers—leading to undesired dipeptide formation, as seen with free proline.

Alternative protecting groups such as Alloc (allyloxycarbonyl) or photolabile groups—used for Lys side chains—are associated with side reactions and are difficult to scale industrially for repetitive α-amino protection–deprotection cycles. Moreover, while developing a new solid support or coupling reagent involves a single molecule, a new α-amino protecting group requires hundreds to thousands of new derivatives, since the current commercial Fmoc-amino acid library contains over one thousand components. This represents a major obstacle to Fmoc replacement.

An underexplored alternative involves non-covalent masking of the amino group's nucleophilicity. The pioneering work of Paolo Mascagni,[24] who employed crown ethers for this purpose, deserves renewed attention. Such masking agents could, in principle, be recycled, as their use does not require bond formation or cleavage in the protection/deprotection cycle.

Side-chain Protecting Groups

There is broad consensus in the peptide community that side chains of trifunctional amino acids should be protected with acid-labile groups. For residues such as Lys, Cys, Asp, and Glu, protection is mandatory due to the intrinsic reactivity of their functional groups. In contrast, protection for Arg, His, Trp, Asn, and Gln can sometimes be omitted, though unprotected forms may lead to side reactions that limit their applicability in large-scale synthesis.[25,26,27] The development of transient protecting groups—able to temporarily mask reactive functions only during coupling—could be a promising direction.

On the other hand, the absence of certain protecting groups can enhance peptide solubility, which may be advantageous or detrimental depending on the synthetic strategy. In hybrid approaches (e.g., coupling of protected fragments in solution), partially deprotected peptides obtained after cleavage from the resin or soluble tag may exhibit improved solubility, facilitating fragment condensation and offering potential process benefits.

Solid Supports

Polystyrene (PS) resins remain the most widely used supports in Solid-Phase Peptide Synthesis (SPPS), both in research and industrial settings. These resins are mechanically robust, chemically stable, provide good loadings, and are available on the multi-kilogram scale at reasonable cost.

However, the synthesis of long or aggregation-prone peptides has encouraged the adoption of more hydrophilic resins. The first generation of such materials was polyethylene glycol (PEG)–grafted PS resins (Tentagel, HiCore, Octagel, PS-PEG are currently the only commercially available), which outperform PS alone.[28] Although PEGA[29] and ChemMatrix[30] (full-PEG resins) are no longer commercially available, they are still recognized as superior to both PS and PEG-PS resins in terms of performance.

The improved behavior of PEG-PS and PEG resins over PS is largely attributed to their greater swelling capacity. For many years, high swelling was regarded as a synonym for high resin quality. However, excessive swelling also

implies the need for larger solvent volumes, which, in large-scale peptide production, translates into larger reactor sizes for equivalent peptide output. This is technically inefficient and contrary to the principles of Green Chemistry, which advocate minimizing solvent use. Consequently, the use of more rigid resins is now being explored. These materials allow reduced solvent consumption during washings (from roughly 10 volumes per gram of resin down to 3–5), enable higher-concentration reactions, and permit the use of smaller reactors for equivalent peptide quantities.

Coupling Reagents

A wide range of coupling reagents is commercially available to meet the diverse requirements of SPPS.[31] Among these, derivatives of 1-hydroxy-7-azabenzotriazole (HOAt)[32] and Oxyma[33] are particularly efficient. It is important to note that, in most cases, low coupling yields arise not from the reagent's inefficiency but from aggregation of the growing peptide chain, a problem that cannot be solved simply by changing the coupling reagent.

With the emergence of LPPS in its liquid–liquid extraction format, further research should focus on traceless coupling reagents or those whose by-products are water-soluble. EDC remains an interesting candidate, although it is insoluble in most organic solvents and performs less efficiently than other carbodiimide-based reagents.

Solvents

Historically, dichloromethane (DCM) and later N,N-dimethylformamide (DMF) have been the solvents of choice in SPPS. The use of DCM is now prohibited in most countries, and the use of DMF and other amide-based solvents is increasingly restricted.[34]

To date, no single solvent has successfully replaced DMF. Mixtures of ethyl acetate (EtOAc) with N-butylpyrrolidone (NBP)[35] or with dimethyl sulfoxide (DMSO)[36] are currently the most widely adopted in large-scale synthesis. Further development of alternative solvent systems, particularly for PS-based resins, remains an important research priority.

Until now, most efforts have focused on identifying green solvents compatible with PS resins, but a more holistic approach is needed—one that develops new resins and new solvents in parallel, ensuring mutual compatibility within a sustainable framework.

Although water is often proposed as the ultimate green solvent, its use is not without controversy. While water is non-toxic and safe to handle, it is difficult and expensive to recycle or dispose of, and it remains a scarce resource in many parts of the world. Moreover, many Process Mass Intensity (PMI) analyses omit the contribution of water, leading to an unfair comparison with other solvents.

Liquid-Phase Peptide Synthesis (LPPS)

As discussed earlier, LPPS has recently emerged as a powerful strategy within the peptide field. However, a key limitation is the broad intellectual property coverage surrounding many tags and other proprietary reagents essential for efficient LPPS operation. In this sense, LPPS is still in its early developmental stage, and much research is required to develop: (i) new tags (both for precipitation and extraction modes); (ii) compatible green solvents; (iii) effective protecting-group removal reagents, and (iv) general strategies for process optimization. To de-risk adoption, PDHC is curating case studies and fostering open benchmarking templates (cycle time, solvent volume per residue, and waste streams) to enable apples-to-apples comparison between SPPS, LPPS, and hybrid routes.

While there is little doubt that LPPS offers great potential for the synthesis of small- and medium-size peptides—including protected intermediates used in hybrid SPPS/solution strategies—it remains necessary to validate LPPS for the multi-kilogram synthesis of large peptides under industrial conditions.

Two-Step vs. Four-Step Peptide Bond Formation

Traditionally, the SPPS peptide-bond formation cycle involves

four steps: (i) coupling; (ii) washing; (iii) α-amino deprotection, and (iv) washing again. To reduce both reaction time (particularly considering the time-consuming filtrations at scale) and solvent consumption, this cycle can be simplified to two steps: coupling, followed directly by addition of the deprotection reagent without intermediate washing, followed by a final washing step. This two-step approach was first implemented in CEM's microwave-assisted synthesizers[37] and later extended to other SPPS configurations.[38] Interestingly, this simplified approach is even more commonly applied in LPPS than in traditional SPPS, owing to the greater homogeneity of liquid-phase systems. Community SOPs that define guardrails (e.g., acceptable residual activator and base thresholds) would further standardize two-step cycles; PDHC is assembling these checklists from contributors across academia and CDMOs.

Native Chemical Ligation (NCL)

Given that both SPPS and LPPS become increasingly challenging as peptide length grows—and that hybrid methods (solution-phase coupling of protected peptide fragments obtained by SPPS or LPPS) often face solubility issues with protected intermediates—the ideal scenario would involve coupling unprotected peptide fragments. These fragments, which themselves can be synthesized via SPPS or LPPS, are joined directly in aqueous media through Native Chemical Ligation (NCL).

To date, and to the best of our knowledge, tirzepatide remains the only industrially produced large peptide obtained through an NCL-based approach.[39] There is no doubt that NCL will play an increasingly important role in the large-scale synthesis of long peptides in the near future. However, to fully realize this potential, fine-tuning will be required in three key areas: (i) the synthesis of unprotected thioester peptides; (ii) the selection and temporary protection of the N-terminal β-thiol amino acid in each fragment, and (iii) the optimization of desulfurization protocols to regenerate the native residues.

Given NCL's growing industrial relevance, PDHC is facilitating shared learnings on thioester access, temporary β-thiol installation/removal, and flow-enabled desulfurization to improve robustness at scale.

Enzymatic Coupling of Unprotected Peptide Fragments

A second promising approach for the ligation of unprotected fragments relies on enzymatic coupling methods. Considering that the assembly of a large peptide typically involves only three or four fragment couplings, this strategy is practically feasible at small scale, as demonstrated by technologies such as EnzyTag.[40]

The main limitation, however, lies in the preparation of unprotected peptide fragments bearing an activated ester at the C-terminal residue, which remains a major challenge for large-scale applications. Nevertheless, enzymatic coupling offers remarkable selectivity and mild reaction conditions, making it an attractive complement to chemical ligation strategies.

A community data room aggregating enzyme panels, substrate scope, and impurity profiles—hosted under PDHC—would accelerate method selection for specific fragment sets.

Biotechnological vs. Chemical Strategies

From a financial and environmental standpoint, biotechnological approaches are generally more favorable than purely chemical ones. However, they typically require longer development times, and by the time a biotechnological route becomes feasible, a chemical process is often already well-established.

Moreover, current trends in clinical and marketed peptide therapeutics show an increasing prevalence of non-proteinogenic amino acids in their sequences. This structural complexity limits the applicability of biotechnological methods, which rely on the proteinogenic amino acid repertoire. Thus, chemical synthesis remains indispensable for next-generation peptide drug candidates.

Working with our EBN and academic members the PDHC can help triage candidates early—matching sequence features (e.g., non-canonical load, macrocyclization, conjugations) to

the most viable manufacturing route

Final Considerations

The new demands of the pharmaceutical industry—namely, the production of large, branched, and cyclic peptides containing non-proteinogenic residues—are opening new directions for synthesis innovation. While SPPS remains the cornerstone of the field, the need to reduce solvent consumption and reactor footprint has accelerated the growth of LPPS and hybrid SPPS/solution strategies. One-pot (two-step) SPPS cycles, in which α-amino deprotection follows coupling without intermediate isolation, can substantially cut time and solvent use, aligning with Green Chemistry principles. In both SPPS and LPPS, low-swelling or rigid resins and traceless coupling reagents represent realistic near-term improvements. For large peptides, fragment coupling through NCL or enzymatic ligation continues to expand in scope, while efforts to minimize protecting-group use promise better atom economy and solubility management.

Amid these scientific and engineering challenges, the Peptide Drug Hunting Consortium (PDHC) can play a catalytic role by operationalizing collaboration. Through its triple-helix model—linking academia, CDMOs, and pharmaceutical developers—PDHC aims to:

- Standardize Green Synthesis metrics (PMI, solvent volume per residue, energy footprint) to benchmark SPPS, LPPS, and hybrid routes.
- Build a shared SOP Commons for one-pot SPPS and LPPS cycles, including impurity thresholds and resin/solvent compatibility maps.
- Curate NCL and enzymatic ligation playbooks, covering thioester preparation, β-thiol protection strategies, and desulfurization protocols.
- Create a route-triage framework to match sequence features—non-canonical load, conjugations, macrocyclization motifs—to optimal manufacturing approaches.
- Establish training and mentorship programs that address the global shortage of process-savvy peptide chemists.

By combining technical rigor with collective execution, PDHC transforms sustainability from a moral imperative into an innovation driver. Reducing solvent intensity, improving atom economy, and accelerating the validation of scalable synthetic routes are not only environmental gains—they are the foundation for sustaining the momentum of the Peptide Golden Era.

References

1. du Vigneaud, V.; Ressler, C.; Swan, J. M.; Roberts, C. W.; Katsoyannis, P. G., The Synthesis of Oxytocin1. Journal of the American Chemical Society 1954, 76 (12), 3115-3121.

2. Merrifield, R. B., Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society 1963, 85 (14), 2149-2154.

3. Marshall, G. R., The early years—Across the bench from Bruce (1963–1966). Peptide Science 2008, 90 (3), 190-199.

4. Carpino, L. A.; Han, G. Y., 9-Fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group. Journal of the American Chemical Society 1970, 92 (19), 5748-5749.

5. Atherton, E.; Logan, C. J.; Sheppard, R. C., Peptide synthesis. Part 2. Procedures for solid-phase synthesis using Nα-fluorenylmethoxycarbonylamino-acids on polyamide supports. Synthesis of substance P and of acyl carrier protein 65–74 decapeptide. J. Chem. Soc., Perkin Trans. 1 1981, (0), 538-546.

6. Chang, C.-D.; Felix, A. M.; Jimenez, M. H.; Meienhofer, J., Solid-Phase Peptide Synthesis of Somatostatin using Mild Base Cleavage of Nα-9-Fluorenylmethyloxycarbonylamino Acids. International Journal of Peptide and Protein Research 1980, 15 (5), 485-494.

7. Rivier, J. E., Use of Trialkyl Ammonium Phosphate (TAAP) Buffers in Reverse Phase HPLC for High Resolution and High Recovery of Peptides and Proteins. J. Liq. Chromatogr. 1978, 1 (3), 343-366.

8. Dawson, P. E.; Muir, T. W.; Clark-Lewis, I.; Kent, S. B. H., Synthesis of Proteins by Native Chemical Ligation. Science 1994, 266 (5186), 776-779.

9. Bray, B. L., Large-scale manufacture of peptide therapeutics by chemical synthesis. Nature Reviews Drug Discovery 2003, 2 (7), 587-593.

10. Chatzi, K. B. O.; Gatos, D.; Stavropoulos, G., 2-Chlorotrityl chloride resin. International Journal of Peptide and Protein Research 1991, 37 (6), 513-520.

11. Frederick, M. O.; Boyse, R. A.; Braden, T. M.; Calvin, J. R.; Campbell, B. M.; Changi, S. M.; Coffin, S. R.; Condon, C.; Gowran, O.; McClary Groh, J.; Groskreutz, S. R.; Harms, Z. D.; Humenik, A. A.; Kallman, N. J.; Klitzing, N. D.; Kopach, M. E.; Kretsinger, J. K.; Lambertus, G. R.; Lampert, J. T.; Maguire, L. M.; Moynihan, H. A.; Mullane, N. S.; Murphy, J. D.; O'Mahony, M. E.; Richey, R. N.; Seibert, K. D.; Spencer, R. D.; Strege, M. A.; Tandogan, N.; Torres Torres, F. L.; Tsukanov, S. V.; Xia, H., Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing. Organic Process Research & Development 2021, 25 (7), 1628-1636.

12. Anastas, P.; Eghbali, N., Green chemistry: principles and practice. Chem. Soc. Rev. 2010, 39 (1), 301-312.

13. Bayer, E.; Mutter, M., Liquid Phase Synthesis of Peptides. Nature 1972, 237 (5357), 512-513.

14. Sharma, A.; Kumar, A.; de la Torre, B. G.; Albericio, F., Liquid-Phase Peptide Synthesis (LPPS): A Third Wave for the Preparation of Peptides. Chemical Reviews 2022, 122 (16), 13516-13546.

15. Sharma, A.; Kumar, A.; de la Torre, Beatriz G.; Albericio, F., Controversial Nomenclature in Peptide Synthesis: A Call for Clarity. J. Pept. Sci. 2025, 31 (9), e70044.

16. Passioura, T.; Katoh, T.; Goto, Y.; Suga, H., Selection-Based Discovery of Druglike Macrocyclic Peptides. 2014, 83 (Volume 83, 2014), 727-752.

17. Winter, G., Harnessing Evolution to Make Medicines (Nobel Lecture). Angew. Chem. Int. Ed. 2019, 58 (41), 14438-14445.

18. Tornøe, C. W.; Christensen, C.; Meldal, M., Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides. The Journal of Organic Chemistry 2002, 67 (9), 3057-3064.

19. Dawson, P. E., Native Chemical Ligation Combined with Desulfurization and Deselenization: A General Strategy for Chemical Protein Synthesis. Isr. J. Chem. 2011, 51 (8-9), 862-867.

20. Barany, G.; Merrifield, R. B., A new amino protecting group removable by reduction. Chemistry of the dithiasuccinoyl (Dts) function. Journal of the American Chemical Society 1977, 99 (22), 7363-7365.

21. Carpino, L. A.; Ismail, M.; Truran, G. A.; Mansour, E. M. E.; Iguchi, S.; Ionescu, D.; El-Faham, A.; Riemer, C.; Warrass, R., The 1,1-Dioxobenzo[b]thiophene-2-ylmethyloxycarbonyl (Bsmoc) Amino-Protecting Group. *The Journal of Organic Chemistry* 1999, *64* (12), 4324-4338.

22. Sabirov, A. N.; Kim, Y.-D.; Kim, H.-J.; Samukov, V. V. J. P.; Letters, P., Fmoc-and Nsc-groups as a base labile N (a)-amino protection: a comparative study in the automated SPPS. 1997, *4* (5), 307-312.

23. Knauer, S.; Koch, N.; Uth, C.; Meusinger, R.; Avrutina, O.; Kolmar, H., Sustainable peptide synthesis enabled by a transient protecting group. *Angew. Chem. Int. Ed.* 2020, *59* (31), 12984-12990.

24. Hyde, C. B.; Mascagni, P., The use of crown ethers in peptide chemistry: Part 3 synthesis of an enkephalin derivative using 18-crown-6 as a non-covalent amino protecting group. *Tetrahedron Letters* 1990, *31* (3), 399-402.

25. Hojo, K.; Manabe, Y.; Uda, T.; Tsuda, Y., Water-Based Solid-Phase Peptide Synthesis without Hydroxy Side Chain Protection. The Journal of Organic Chemistry 2022, 87 (17), 11362-11368.

26. Yang, Y.; Hansen, L.; Ryberg, P., Side-Chain Unprotected Fmoc-Arg/His/Tyr-OH Couplings and Their Application in Solid-Phase Peptide Synthesis through a Minimal-Protection/Green Chemistry Strategy. Organic Process Research & Development 2022, 26 (5), 1520-1530.

27. Fantoni, T.; Orlandin, A.; Di Stefano, I.; Macis, M.; Tolomelli, A.; Ricci, A.; Cabri, W.; Ferrazzano, L., Solid phase peptide synthesis using side-chain unprotected arginine and histidine with Oxyma Pure/TBEC in green solvents. Green Chem. 2024, 26 (21), 10929-10939.

28. Wang, Z.; Yang, R.; Zhu, J.; Zhu, X., PEG-related polymer resins as synthetic supports. Science China Chemistry 2010, 53 (9), 1844-1852.

29. Ramsing, M. L.; Warming, C.; Meldal, M., Green Resins for All: Sustainable Preparation of PEGA Resin for Peptide and Protein Synthesis and Immobilization. *ACS Applied Materials & Interfaces* 2025, *17* (17), 25764-25773.

30. Garcia-Martin, F.; Quintanar-Audelo, M.; Garcia-Ramos, Y.; Cruz, L. J.; Gravel, C.; Furic, R.; Cote, S.; Tulla-Puche, J.; Albericio, F., ChemMatrix, a Poly(ethylene glycol)-Based Support for the Solid-Phase Synthesis of Complex Peptides. *J. Comb. Chem. 2006, 8 (2), 213-220.*

31. El-Faham, A.; Albericio, F., Peptide Coupling Reagents, More than a Letter Soup. Chem. Rev. (Washington, DC, U. S.) 2011, 111 (11), 6557-6602.

32. Carpino, L. A., 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. Journal of the American Chemical Society 1993, 115 (10), 4397-4398.

33. Subiros-Funosas, R.; Prohens, R.; Barbas, R.; El-Faham, A.; Albericio, F., Oxyma: An Efficient Additive for Peptide Synthesis to Replace the Benzotriazole-Based HOBt and HOAt with a Lower Risk of Explosion[1]. Chem. - Eur. J. 2009, 15 (37), 9394-9403, S9394/1-S9394/34.

34. Sherwood, J.; Albericio, F.; de la Torre, B. G., N,N-Dimethyl Formamide European Restriction Demands Solvent Substitution in Research and Development. ChemSusChem 2024, 17 (8), e202301639.

35. Erny, M.; Lundqvist, M.; Rasmussen, J. H.; Ludemann-Hombourger, O.; Bihel, F.; Pawlas, J., Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions. Organic Process Research & Development 2020, 24 (7), 1341-1349.

36. Martin, V.; Jadhav, S.; Egelund, P. H. G.; Liffert, R.; Johansson Castro, H.; Krüger, T.; Haselmann, K. F.; Thordal Le Quement, S.; Albericio, F.; Dettner, F.; Lechner, C.; Schönleber, R.; Pedersen, D. S., Harnessing polarity and viscosity to identify green binary solvent mixtures as viable alternatives to DMF in solid-phase peptide synthesis. Green Chem. 2021, 23 (9), 3295-3311.

37. Collins, J. M.; Singh, S. K.; White, T. A.; Cesta, D. J.; Simpson, C. L.; Tubb, L. J.; Houser, C. L., Total wash elimination for solid phase peptide synthesis. Nature Communications 2023, 14 (1), 8168.

38. Kumar, A.; Sharma, A.; de la Torre, B. G.; Albericio, F., In situ Fmoc removal – a sustainable solid-phase peptide synthesis approach. Green Chem. 2022, 24 (12), 4887-4896.

39. Jalan, A.; Murzinski, E.; Jansen, P.; Embry, M.; Scherer, R.; Moomaw , J.; Williams, K.; Fisher, C.; Guinn, E.; Teng, J.; Kopach, M. E., A Novel Hybrid SPPS/LPPS Strategy for the Synthesis of Tirzepatide via Native Chemical Ligation. ChemRxiv. 2025, doi:10.26434/chemrxiv-2025-g9qcl.

40. Rizzo, S.; Toplak, A.; Macis, M.; Ferrazzano, L.; Ricci, A.; Tolomelli, A.; Cabri, W., A Sustainable Chemo-Enzymatic Approach to the Synthesis of Liraglutide. ACS Sustainable Chemistry & Engineering 2024, 12 (45), 16791-16799.

Our Peptide Drug Hunting Raison d'être

Innovative Science & Technology Empowering Breakthrough Medicines

Our Peptide Drug Hunting Initiatives

- De Novo Design
- Synthesis Innovation
  - Enabling Complex Peptide Synthesis
  - Scalability and R&D Cost Challenges
  - Process Efficiency & Green Chemistry
- Translation into the Clinic

Contact Us

contact@peptidedrughunting.org

www.peptidedrughunting.org

www.linkedin.com/company/peptide-drug-hunting